EN DE
Watch Wuhan Hiteck Biological Pharma Co Ltd for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Wuhan Hiteck Biological Pharma Co Ltd (300683) fair value: what the stock is really worth

As of Nov 20, 2026: fair value (intrinsic value) of Wuhan Hiteck Biological Pharma Co Ltd stock ¥16.13, price ¥18.79, that is 14.2% below the price, quality 44 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently applies, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE1000034C5

WH Wuhan Hiteck Biological Pharma Co Ltd logo Thin data Nov 16, 2026

Wuhan Hiteck Biological Pharma Co Ltd

300683 · SHE

Expensive (fair value 14% below the price), weak company and falling price: meets none of the 3 rules.

Follow free in the weekly email
Low debt 
Quality 44/100 
Revenue last quarter 40% below a year ago. 
Fair value ¥16.13 · Overvalued 
Falling price (downtrend) 
Weak Growth (revenue 5y +0.7 %/yr in CNY) 
Loss-making · -44.4% net margin (TTM) 
Negative free cash flow 
Trails peers (2/11) 
Narrow moat 12/100
Thin data 
Estimate
Watch Wuhan Hiteck Biological Pharma Co Ltd for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥69.31 ¥18.79 Fair Value ¥16.13 Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range ¥18.79 – ¥69.31 · fair‑value band ¥12.10 – ¥20.16 · the ¥18.79 price screens above the ¥16.13 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Wuhan Hiteck Biological Pharma Co in your weekly email

Every Wednesday you see whether Wuhan Hiteck Biological Pharma Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China.

Show moreShow less

Its products include Epramine for injection; mouse nerve growth factor for injection; Anewway, a mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome; adenosine cyclophosphate for injection that is used for angina pectoris, myocardial infarction, myocarditis, and cardiogenic shock; aciclovir dispersible tablets for the treatment of genital herpes virus infection, herpes zoster, and immune deficiency chickenpox; Pentoxone theobromine injection; Roxatidine Acetate Hydrochloride for Injection; and Terizazole phosphate for injection.

The company also provides measles and rubella virus nucleic acid detection kits; isolation and identification tubes and kits for mycoplasma; and bacterial vaginosis (BV) rapid test kits, as well as diagnostic kits for novel coronavirus N-Protein.

In addition, it offers diagnostic kits for IgG antibody to measles virus, hydatid, toxoplasma, rubella virus, cytomegalo virus, and herpes simplex virus I/II; diagnostic kits for IgM antibody to measles virus, herpes simplex virus I/II, cytomegalo virus, rubella virus, and toxoplasma; and diagnostic kits for a "Thalassemia.

Further, the company provides Lopinavir and Ritonavir APIs, and intermediates. It offers its products in the field of nervous system and oncology. Wuhan Hiteck Biological Pharma Co.,Ltd was founded in 1992 and is based in Wuhan, China.

Stock analysis

Wuhan Hiteck Biological Pharma Co Ltd (300683) currently trades at ¥18.79, while our estimate is ¥16.13, 14% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: ¥12.10 (bear) to ¥20.16 (bull), the price of ¥18.79 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.

Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.

Wuhan Hiteck Biological Pharma Co Ltd reported revenue of 541M CNY in FY2025 versus 615M CNY in FY2021, a compound −3.1%/yr. Reported net income was −231M CNY in FY2025.

Key figures

Market cap 2.5B CNY (≈ $371M) Small · P/S ratio 6.78 · EPS (TTM) ¥-1.47 · Dividend yield 0.6% · Net margin −44.4% · Return on equity −9.1% · Return on assets (EBIT) −2.3% (5-year average) · Operating margin −55.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 61% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −26% fair-value upside, at −14%, 300683 screens cheaper than that median.

Fair Value

Bear ¥12.10 Fair Value ¥16.13 Bull ¥20.16
Price ¥18.79 · Downside -14.2%
Estimate. None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 44/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 4
How much profit the company makes from its sales and capital
Quality Growth 22
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 96
Debt, balance sheet and risk of trouble
Investment 86
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 3
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 77
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 6/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
−16.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.7%
Start year 2020 (pandemic). Over 10 years: −2.2% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−6.7% (2020) → −22.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

300683 screens overvalued: fair value 14% below the price. Compare with Merck KGaA →

Compare Wuhan Hiteck Biological Pharma Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 611 stocks

Beats the industry median on 2/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 44 · Below median
Fair Value upside −14.2% · Below median
Profitability
Return on assets −9.0% · Bottom 25%
Net margin (12 months) −44.4% · Bottom 25%
Operating margin (12 months) −55.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −39.9% · Bottom 25%
Dividend yield (12 months) 0.6% · Bottom 25%
Balance sheet
Debt / equity 0.01× · Lowest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 1.15× · Cheaper than median
P/S (12 months) 5.71× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)14 · sector 22
FUTURE (revenue growth)0 · sector 28
PAST (return on equity)0 · sector 25
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)12 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.11 $113.53 +44% vs 300683
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥47.00 ¥51.70 +10% vs 300683
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,884.90 ₹1,982.92 +5% vs 300683
Haleon plc HLN $9.07 $8.47 −7% vs 300683
Merck KGaA MRK €146.45 €108.83 −26% vs 300683
Galderma Group GALD CHF 182.85 CHF 112.84 −38% vs 300683
Teva Pharmaceutical Industries Limited TEVA $39.23 $20.74 −47% vs 300683
Takeda Pharmaceutical Company TAK $21.77 $11.26 −48% vs 300683
Sandoz Group SDZ CHF 80.50 CHF 40.87 −49% vs 300683
Divi's Laboratories Limited DIVISLAB ₹11,180.50 ₹1,566.89 −86% vs 300683

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Wuhan Hiteck Biological Pharma Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Wuhan Hiteck Biological Pharma Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/300683

Frequently asked questions

Is Wuhan Hiteck Biological Pharma Co Ltd (300683) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is ¥16.13 versus a price of ¥18.79, about 14% lower (overvalued).
What is the fair value of 300683?
Our estimate for Wuhan Hiteck Biological Pharma Co Ltd is ¥16.13 (as of Nov 16, 2026), built from audited fundamentals. The current price: ¥18.79.
What is the quality score of 300683?
Wuhan Hiteck Biological Pharma Co Ltd has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Wuhan Hiteck Biological Pharma Co Ltd (300683)?
We do not set a price target; the yardstick is our estimate of ¥16.13 (as of Nov 16, 2026). Cautious scenario ¥12.10, optimistic scenario ¥20.16. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently applies, not an analyst target.
What is the Wuhan Hiteck Biological Pharma Co Ltd stock forecast for 2026?
Our estimate puts fair value at ¥16.13, about 14% lower versus a price of ¥18.79 (overvalued). Cautious scenario ¥12.10, optimistic scenario ¥20.16. The calculation is refreshed regularly with new filings.
What is the revenue of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
Wuhan Hiteck Biological Pharma Co Ltd reported trailing-twelve-month revenue of about 433M CNY (latest available figure, as of Nov 16, 2026).
Does Wuhan Hiteck Biological Pharma Co Ltd pay a dividend?
Wuhan Hiteck Biological Pharma Co Ltd currently shows a dividend yield of 0.61% relative to its recent price (as of Nov 16, 2026).
How much is the dividend of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
Wuhan Hiteck Biological Pharma Co Ltd has a dividend yield of 0.6%.
What is the intrinsic value of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Wuhan Hiteck Biological Pharma Co Ltd it is ¥16.13 per share (as of Nov 16, 2026), against a price of ¥18.79.
Is Wuhan Hiteck Biological Pharma Co Ltd stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 300683 trades above its calculated fair value: price ¥18.79, fair value ¥16.13, a gap of about −14% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300683?
No. The price is what the market pays today (¥18.79); the fair value is what the company's own numbers justify (¥16.13). For Wuhan Hiteck Biological Pharma Co Ltd the two are ¥2.66 per share apart. That gap is exactly why we show both numbers side by side.
How much is Wuhan Hiteck Biological Pharma Co Ltd worth?
The market values Wuhan Hiteck Biological Pharma Co Ltd at about 2.5B CNY (market capitalisation, as of Nov 16, 2026). Per share that is ¥18.79; our models calculate a fair value of ¥16.13 per share.
What do the bullish and bearish scenarios say about 300683?
Our models span a range for Wuhan Hiteck Biological Pharma Co Ltd: cautious scenario ¥12.10, base ¥16.13, optimistic ¥20.16 per share (as of Nov 16, 2026, price ¥18.79). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
Balance-sheet figures for Wuhan Hiteck Biological Pharma Co Ltd (as of Nov 16, 2026): return on equity −9.1%, debt of 0.01 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is 300683 from its 52-week high?
Wuhan Hiteck Biological Pharma Co Ltd trades at ¥18.79, about 61% below its 52-week high of ¥48.78 and at the low of ¥18.79 (as of Nov 20, 2026). Distance from the high says nothing about value: that is what the fair value of ¥16.13 is for.
Which stocks are comparable to Wuhan Hiteck Biological Pharma Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Wuhan Hiteck Biological Pharma Co Ltd stock attractive at the current price?
The data as of Nov 16, 2026: price ¥18.79, calculated fair value ¥16.13 (−14%), Quality Score 44/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 10.1% above its aggregate fair value. Wuhan Hiteck Biological Pharma Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
The closing price on Nov 20, 2026 was ¥18.79. Our estimate is ¥16.13, about 14% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Wuhan Hiteck Biological Pharma Co Ltd right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Wuhan Hiteck Biological Pharma Co Ltd

How large is the market capitalisation of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
The market capitalisation of Wuhan Hiteck Biological Pharma Co Ltd is 2.5B CNY (≈ $371M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
The price-to-sales ratio of Wuhan Hiteck Biological Pharma Co Ltd is 6.78 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
Earnings per share at Wuhan Hiteck Biological Pharma Co Ltd are ¥-1.47. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
The dividend yield of Wuhan Hiteck Biological Pharma Co Ltd is 0.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
The net margin of Wuhan Hiteck Biological Pharma Co Ltd is −44.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
The return on equity (ROE) of Wuhan Hiteck Biological Pharma Co Ltd is −9.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
On an EBIT basis the return on assets of Wuhan Hiteck Biological Pharma Co Ltd is −2.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
The operating margin of Wuhan Hiteck Biological Pharma Co Ltd is −55.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Wuhan Hiteck Biological Pharma Co Ltd (300683)?
Revenue at Wuhan Hiteck Biological Pharma Co Ltd is down 39.9% in the last quarter versus the same quarter a year earlier (3y avg −7.7%). How much revenue grew in the last quarter versus the same quarter a year earlier (YoY). The 3-year average next to it puts the single quarter in context.
How fast are earnings growing at Wuhan Hiteck Biological Pharma Co Ltd (300683)?
Earnings per share at Wuhan Hiteck Biological Pharma Co Ltd are down 57.1% in the last quarter versus the same quarter a year earlier. How much earnings per share grew in the last quarter versus the same quarter a year earlier.
How much free cash flow does Wuhan Hiteck Biological Pharma Co Ltd (300683) generate?
The free cash flow of Wuhan Hiteck Biological Pharma Co Ltd is −127M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Wuhan Hiteck Biological Pharma Co Ltd (300683) hold?
Wuhan Hiteck Biological Pharma Co Ltd holds more cash than debt, 395M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Wuhan Hiteck Biological Pharma Co Ltd in the live analysis

One click puts Wuhan Hiteck Biological Pharma Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.